



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/195,368	11/18/1998	AVI J. ASHKENAZI	11669.26US03	4244
7590	01/14/2005			
GENENTECH 1 DNA WAY SO. SAN FRANCISCO, CA 94080-4990			EXAMINER NICKOL, GARY B	
			ART UNIT	PAPER NUMBER
			1642	

DATE MAILED: 01/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 09/195,368	<b>Applicant(s)</b> ASHKENAZI ET AL.	
	<b>Examiner</b> Gary B. Nickol Ph.D.	<b>Art Unit</b> 1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 21 October 2004.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-9 and 27-59 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 59 is/are allowed.
- 6) ☒ Claim(s) 1-9 and 27-58 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input checked="" type="checkbox"/> Other: <u>Sequence Error Report</u> .            |

Art Unit: 1642

Re: Ashkenazi et al.

Date of priority: 11/18/1997

***Response to Arguments***

The Response filed 10-21-04 in response to the Office Action of April 22, 2004 is acknowledged and has been entered.

Claims 1-9, and 27-59 remain pending and under consideration.

**The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.**

The specification remains objected to under the brief description of Figures 2 and 7 for improper disclosure of amino acid sequences (i.e. TNF- $\alpha$ , APO2L, C995L, hGITR) without respective sequence identifiers. Although applicants have amended the specification, it is noted that the computer readable format contained errors (see attached copies of errors). Applicant must provide a computer readable form (CRF) copy of the sequence listing, an initial or substitute paper copy of the sequence listing, as well as any amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e-f) or 1.825(b) or 1.825(d).

Art Unit: 1642

Claims 1-9, and 27-58 remain rejected under 35 USC 102(e) as being anticipated by the disclosure of Yu *et al.* (US 5,988,171,) for the reasons of record. With regards to applicant's reference to the decisions of *In re Wertheim*, such arguments are not persuasive because applicants failed to characterize or compare the specific decisions from *In re Wertheim* with the outstanding rejections of the present application. Furthermore, with regards to MPEP 2136.04, sub-heading IV, applicant's arguments are not persuasive because that section of the MPEP is concerned with determining critical reference dates, in particular, when the parent reference is based from a continuation-in-part. Overall, applicant's arguments have remained substantially the same as those presented earlier. Thus, for the reasons of record, applicant's arguments are not persuasive and the rejection is maintained.

All other rejections and or objections are withdrawn in view of applicant's amendments and arguments there to.

Claim 59 appears allowable.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1642

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835. The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary B. Nickol Ph.D.  
Primary Examiner  
Art Unit 1642

GBN

  
**GARY NICKOL**  
**PRIMARY EXAMINER**

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



**RAW SEQUENCE LISTING**  
**ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: US/09/195,368B  
Source: IFW16  
Date Processed by STIC: 10-28-04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER** **VERSION 4.2 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):  
U.S. Patent and Trademark Office, 220 20<sup>th</sup> Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

# Raw Sequence Listing Error Summary

## ERROR DETECTED

## SUGGESTED CORRECTION

SERIAL NUMBER:

US/09/195,368B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1           Wrapped Nucleics  
              Wrapped Aminos      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2           Invalid Line Length      The rules require that a line not exceed 72 characters in length. This includes white spaces.

3           Misaligned Amino  
              Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4           Non-ASCII      The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5           Variable Length      Sequence(s)      contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>.<223> section that some may be missing

6           PatentIn 2.0  
              "bug"      A "bug" in PatentIn version 2.0 has caused the <220>.<223> section to be missing from amino acid sequences(s)     . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>.<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>.<223> sections for Artificial or Unknown sequences.

7           Skipped Sequences  
              (OLD RULES)      Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence:  
    (2) INFORMATION FOR SEQ ID NO: X (insert SEQ ID NO where "X" is shown)  
    (i)      SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading!)  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: X (insert SEQ ID NO where "X" is shown)  
    This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES" response to include the skipped sequences

8           Skipped Sequences  
              (NEW RULES)      Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence:  
    <210> sequence id number  
    <400> sequence id number  
    000

9           Use of n's or Xaa's  
              (NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
    Per 1.823 of Sequence Rules, use of <220>.<223> is MANDATORY if n's or Xaa's are present  
    In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents

10           Invalid <213>  
              Response      Per 1.823 of Sequence Rules, the only valid <213> responses are Unknown, Artificial Sequence, or scientific name (Genus/species). <220>.<223> section is required when <213> response is Unknown or is Artificial Sequence

11           Use of <220>      Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
    (See "Federal Register," 00/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12           PatentIn 2.0  
              "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13           Misuse of n/Xaa      "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFW16

## RAW SEQUENCE LISTING

DATE: 10/28/2004

PATENT APPLICATION: US/09/195,368B

TIME: 15:22:51

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

W--> 1 Patin Docket Preview - delete

7 <110> APPLICANT: Ashkenazi, Avi J.  
 8 Baker, Kevin P.  
 9 Godowski, Paul J.  
 10 Gurney, Austin L.  
 11 Mark, Melanie R.  
 12 Marsters, Scot A.  
 13 Pitti, Robert M.  
 15 <120> TITLE OF INVENTION: DNA19355 Polypeptide, A Tumor Necrosis Factor Homolog  
 17 <130> FILE REFERENCE: P1150R2  
 19 <140> CURRENT APPLICATION NUMBER: US 09/195,368B  
 20 <141> CURRENT FILING DATE: 1998-11-18  
 22 <150> PRIOR APPLICATION NUMBER: US 60/069,661  
 23 <151> PRIOR FILING DATE: 1997-12-12  
 25 <150> PRIOR APPLICATION NUMBER: US 60/065,635  
 26 <151> PRIOR FILING DATE: 1997-11-18  
 28 <160> NUMBER OF SEQ ID NOS: 15  
 30 <210> SEQ ID NO: 1  
 31 <211> LENGTH: 177  
 32 <212> TYPE: PRT  
 33 <213> ORGANISM: Homo sapiens  
 35 <400> SEQUENCE: 1  
 36 Met Cys Leu Ser His Leu Glu Asn Met Pro Leu Ser His Ser Arg  
 37 1 5 10 15  
 39 Thr Gln Gly Ala Gln Arg Ser Ser Trp Lys Leu Trp Leu Phe Cys  
 40 20 25 30  
 42 Ser Ile Val Met Leu Leu Phe Leu Cys Ser Phe Ser Trp Leu Ile  
 43 35 40 45  
 45 Phe Ile Phe Leu Gln Leu Glu Thr Ala Lys Glu Pro Cys Met Ala  
 46 50 55 60  
 48 Lys Phe Gly Pro Leu Pro Ser Lys Trp Gln Met Ala Ser Ser Glu  
 49 65 70 75  
 51 Pro Pro Cys Val Asn Lys Val Ser Asp Trp Lys Leu Glu Ile Leu  
 52 80 85 90  
 54 Gln Asn Gly Leu Tyr Leu Ile Tyr Gly Gln Val Ala Pro Asn Ala  
 55 95 100 105  
 57 Asn Tyr Asn Asp Val Ala Pro Phe Glu Val Arg Leu Tyr Lys Asn  
 58 110 115 120  
 60 Lys Asp Met Ile Gln Thr Leu Thr Asn Lys Ser Lys Ile Gln Asn  
 61 125 130 135  
 63 Val Gly Gly Thr Tyr Glu Leu His Val Gly Asp Thr Ile Asp Leu  
 64 140 145 150  
 66 Ile Phe Asn Ser Glu His Gln Val Leu Lys Asn Asn Thr Tyr Trp

Does Not Comply  
 Corrected Diskette Needed  
 (pg. 1, 3-4)



## RAW SEQUENCE LISTING

DATE: 10/28/2004

PATENT APPLICATION: US/09/195,368B

TIME: 15:22:51

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

```

67          155          160          165
69 Gly Ile Ile Leu Leu Ala Asn Pro Gln Phe Ile Ser
70          170          175
72 <210> SEQ ID NO: 2
73 <211> LENGTH: 1964
74 <212> TYPE: DNA
75 <213> ORGANISM: Homo sapiens
77 <220> FEATURE:
78 <221> NAME/KEY: unsure
79 <222> LOCATION: 1857, 1875
80 <223> OTHER INFORMATION: n may be any nucleotide
82 <400> SEQUENCE: 2
83 cagctctcat ttctccaaaa atgtgtttga gccacttga aaatatgcct 50
85 ttaagccatt caagaactca aggagctcag agatcatcct ggaagctgtg 100
87 gctcttttgc tcaatagtta tgttgctatt tctttgctcc ttcagttggc 150
89 taatctttat ttttctccaa ttagagactg ctaaggagcc ctgtatggct 200
91 aagtttggac cattaccctc aaaatggcaa atggcatctt ctgaacctcc 250
93 ttgctgtaat aaggtgtctg actggaagct ggagatactt cagaatggct 300
95 tatatttaat ttatggccaa gtggctccca atgcaaacta caatgatgta 350
97 gctccttttg aggtgcggt gtataaaaac aaagacatga tacaactct 400
99 aacaaacaaa tctaaaatcc aaaatgtagg agggacttat gaattgcatg 450
101 ttggggacac catagacttg atattcaact ctgagcatca ggttctaaaa 500
103 aataatacat actggggtat cattttacta gcaaataccc aattcatctc 550
105 ctagagactt gatitgatct cctcattccc ttcagcacat gtagaggtgc 600
107 cagtgggtgg attggagggg gaagatatct aatttctaga gtttgtctgt 650
109 ctacaaaaat caacacaaac agaactcctc tgcacgtgaa ttttcatcta 700
111 tcatgcctat ctgaaagaga ctgaggggaa gagccaaaga cttttggttg 750
113 gatctgcaga aatacttcat taatccatga taaaacaaat atggatgaca 800
115 gaggacatgt gcttttcaaa gaatctttat ctaattcttg aattcatgag 850
117 tggaaaaatg gagttctatt cccatggaag atttacctgg tatgcaaaaa 900
119 ggatctgggg cagtagcctg gctttgttct catattcttg ggctgctgta 950
121 attcattctt ctactactcc catcttctga gaccctccca ataaaaagta 1000
123 gactgatagg atggccacag atatgcctac cataccctac tttagatag 1050
125 gtggtgttag aagataaaga acaatctgag aactattgga atagaggtac 1100
127 aagtggcata aaatggaatg tacgctatct ggaaatttct cttggtttta 1150
129 tcttctcag gatgcagggt gcttataaaa gccttatcaa aggagtcatt 1200
131 ccgaaccttc acgtagagct ttgtgagacc ttactgttgg tgtgtgtgtc 1250
133 taaacattgc taattgtaaa gaaagagtaa ccattagtaa tcattagggt 1300
135 taaccccgaga atggtattat cattactgga ttatgtcatg taatgattta 1350
137 gtatttttag ctagctttcc acagtttgca aagtgtcttc gtaaaacagt 1400
139 tagcaattct atgaagttaa ttgggcaggc atttggggga aaatttttagt 1450
141 gatgagaatg tgatagcata gcatagccaa ctttctcaa ctcataggac 1500
143 aagtgactac aagaggcaat gggtagtccc ctgcattgca ctgtctcagc 1550
145 tttagaattg ttatttctgc tatcgtgtta taagactcta aaacttagcg 1600
147 aattcacttt tcaggaagca tattccccct tagcccaagg tgagcagagt 1650
149 gaagctacaa cagatcttcc ctttaccagc acactttttt ttttttttcc 1700
151 tgcctgaatc agggagatcc aggatgctgt tcaggccaaa tcccaaccaa 1750
153 attccccctt tcactttgca gggcccatct tagtcaaag tgctaacttc 1800
155 taaaataata aatagacta attcaaaatt tttggaatct taaattagct 1850

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/195,368B

DATE: 10/28/2004

TIME: 15:22:51

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

W--> 157 acttgenggt tgcttgttga aaggmatata atgattacat tgtaaacaaa 1900  
 159 tttaaaatat ttatggatat ttgtgaaaag ctgcattatg ttaaataata 1950  
 161 ttacatgtaa agct 1964  
 163 <210> SEQ ID NO: 3  
 164 <211> LENGTH: 38  
 165 <212> TYPE: DNA  
 166 <213> ORGANISM: Unknown  
 168 <220> FEATURE:

W--> 169 <221> NAME/KEY: Unknown Organism  
 170 <222> LOCATION: 1-38

171 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown

173 <400> SEQUENCE: 3

174 gacgacaagc atatgttaga gactgctaag gagccctg 38

176 <210> SEQ ID NO: 4

177 <211> LENGTH: 34

178 <212> TYPE: DNA

179 <213> ORGANISM: Unknown

181 <220> FEATURE:

W--> 182 <221> NAME/KEY: unknown organism

183 <222> LOCATION: 1-34

184 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown

186 <400> SEQUENCE: 4

187 tagcagccgg atcctaggag atgaattggg gatt 34

189 <210> SEQ ID NO: 5

190 <211> LENGTH: 24

191 <212> TYPE: PRT

192 <213> ORGANISM: Unknown

194 <220> FEATURE:

W--> 195 <221> NAME/KEY: unknown organism

196 <222> LOCATION: 1-24

197 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown

199 <400> SEQUENCE: 5

200 Met Gly His His His His His His His His His Ser Ser Gly

201 1 5 10 15

203 His Ile Asp Asp Asp Lys His Met

204 20

206 <210> SEQ ID NO: 6

207 <211> LENGTH: 29

208 <212> TYPE: DNA

209 <213> ORGANISM: Unknown

211 <220> FEATURE:

W--> 212 <221> NAME/KEY: unknown organism

213 <222> LOCATION: 1-29

214 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown

216 <400> SEQUENCE: 6

217 atcagggact ttccgctggg gactttccg 29

219 <210> SEQ ID NO: 7

220 <211> LENGTH: 42

221 <212> TYPE: DNA

Mandatory,  
 if <213> response  
 is Artificial/  
 Unknown, pls explain  
 in section <220> -  
 <223>.  
 Invalid  
 Response

Invalid  
 Response

Invalid  
 Response

Invalid  
 Response

↑ pls see item #  
 // on error sheet.  
 summary 10/28/04

## RAW SEQUENCE LISTING

DATE: 10/28/2004

PATENT APPLICATION: US/09/195,368B

TIME: 15:22:51

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

```

222 <213> ORGANISM: Unknown
224 <220> FEATURE:
W--> 225 <221> NAME/KEY: unknown organism delete
226 <222> LOCATION: 1-42
227 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown
229 <400> SEQUENCE: 7
230 tgtaaaacga cggccagttt ctctcagaga aacaagcaaa ac 42
232 <210> SEQ ID NO: 8
233 <211> LENGTH: 43
234 <212> TYPE: DNA
235 <213> ORGANISM: Unknown
237 <220> FEATURE:
W--> 238 <221> NAME/KEY: unknown organism delete
239 <222> LOCATION: 1-43
240 <223> OTHER INFORMATION: Description of Unknown Organism: Unknown
242 <400> SEQUENCE: 8
243 caggaaacag ctatgaccga agtggaccaa aggtctatcg cta 43
245 <210> SEQ ID NO: 9
246 <211> LENGTH: 126
247 <212> TYPE: PRT
248 <213> ORGANISM: Homo sapien
250 <400> SEQUENCE: 9
251 Glu Thr Ala Lys Glu Pro Cys Met Ala Lys Phe Gly Pro Leu Pro
252 1 5 10 15
254 Ser Lys Trp Gln Met Ala Ser Ser Glu Pro Pro Cys Val Asn Lys
255 20 25 30
257 Val Ser Asp Trp Lys Leu Glu Ile Leu Gln Asn Gly Leu Tyr Leu
258 35 40 45
260 Ile Tyr Gly Gln Val Ala Pro Asn Ala Asn Tyr Asn Asp Val Ala
261 50 55 60
263 Pro Phe Glu Val Arg Leu Tyr Lys Asn Lys Asp Met Ile Gln Thr
264 65 70 75
266 Leu Thr Asn Lys Ser Lys Ile Gln Asn Val Gly Gly Thr Tyr Glu
267 80 85 90
269 Leu His Val Gly Asp Thr Ile Asp Leu Ile Phe Asn Ser Glu His
270 95 100 105
272 Gln Val Leu Lys Asn Asn Thr Tyr Trp Gly Ile Ile Leu Leu Ala
273 110 115 120
275 Asn Pro Gln Phe Ile Ser
276 125
278 <210> SEQ ID NO: 10
279 <211> LENGTH: 150
280 <212> TYPE: PRT
281 <213> ORGANISM: Homo sapien
283 <400> SEQUENCE: 10
284 Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro Gln Ala
285 1 5 10 15
287 Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu
288 20 25 30

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/195,368B

DATE: 10/28/2004

TIME: 15:22:51

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

```

290 Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser
291           35                      40                      45
293 Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln
294           50                      55                      60
296 Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile Ser Arg
297           65                      70                      75
299 Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile
300           80                      85                      90
302 Lys Ser Pro Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys
303           95                      100                     105
305 Pro Trp Tyr Glu Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu
306          110                      115                     120
308 Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu
309          125                      130                     135
311 Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
312          140                      145                     150
314 <210> SEQ ID NO: 11
315 <211> LENGTH: 164
316 <212> TYPE: PRT
317 <213> ORGANISM: Homo sapien
319 <400> SEQUENCE: 11
320 Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly Thr Arg Gly Arg
321   1           5                      10                      15
323 Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu
324           20                      25                      30
326 Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser
327           35                      40                      45
329 Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile His
330           50                      55                      60
332 Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe
333           65                      70                      75
335 Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val
336           80                      85                      90
338 Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu
339           95                      100                     105
341 Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr
342          110                      115                     120
344 Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu
345          125                      130                     135
347 Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp
348          140                      145                     150
350 Met Asp His Glu Ala Ser Phe Phe Gly Ala Gly Leu Val Gly
351          155                      160
353 <210> SEQ ID NO: 12
354 <211> LENGTH: 141
355 <212> TYPE: PRT
356 <213> ORGANISM: Homo sapien
358 <400> SEQUENCE: 12
359 Glu Leu Arg Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg

```

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/195,368B

DATE: 10/28/2004  
TIME: 15:22:52

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; N Pos. 1857,1875 ✓

## VERIFICATION SUMMARY

DATE: 10/28/2004

PATENT APPLICATION: US/09/195,368B

TIME: 15:22:52

Input Set : A:\P1150R2.txt

Output Set: N:\CRF4\10282004\I195368B.raw

L:1 M:259 W: Allowed number of lines exceeded, (1) GENERAL INFORMATION:  
L:157 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:1850  
L:169 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:182 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:195 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:212 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:225 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:7  
L:238 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:8